Korun Pharmaceuticals: Subsidiary Injection of Alipazone Approved for Drug Registration.

Colen Pharmaceutical announced that its subsidiary, Hunan Colen Pharmaceutical Co., Ltd., recently obtained drug registration approval from the National Medical Products Administration for the chemical drug "Aripiprazole for Injection." Aripiprazole for Injection is a long-acting microcrystalline formulation administered once a month. Compared to oral medications, it can improve patient medication compliance, reduce the risk of disease recurrence, lower peak-trough fluctuations in blood drug concentration, enhance medication safety, reduce the burden on healthcare providers, patients, and society. Currently, it has been widely recommended in authoritative guidelines such as the "Chinese Expert Consensus on Maintenance Treatment of Schizophrenia," "Expert Consensus on Long-acting Injectable Antipsychotic Therapy for Schizophrenia," and "Drug Treatment of Schizophrenia: Expert Consensus in Japan" both domestically and internationally. Aripiprazole for Injection is classified as a Category B medical insurance product with projected global sales of approximately $2.2 billion by 2025.